Li Chang is an associate in Goodwin’s Business Law department and a member of its Life Sciences group. Li’s practice covers all phases of the corporate life cycle, from venture financing through initial public offering or acquisition, with a focus on capital markets transactions, such as initial public offerings and other equity offerings. Li also counsels clients on corporate matters, including securities law compliance, corporate governance and strategic transactions.
Experience
- Entrada Therapeutics in connection with its $100 million registered direct offering
- The underwriters of Royalty Pharma’s $1.5 billion senior unsecured notes public offering
- The exclusive placement agent of Acrivon Therapeutics’ $130 million private placement
- Phoenix Biotech Acquisition Corp in connection with its de-SPAC transaction with CERo Therapeutics
- Metagenomi in connection with its $94 million initial public offering
- Sagimet Biosciences in connection with its $85 million initial public offering
- Rocket Pharmaceuticals in connection with its $115 million follow-on offering
- The underwriters of Acrivon Therapeutics’ $100 million initial public offering and concurrent private placement
- Akili Therapeutics in connection with its de-SPAC transaction with Social Capital Suvretta Holdings Corp. I
- Akili in connection with its acquisition through tender offer by Virtual Therapeutics
- Theseus Pharmaceuticals in connection with its 185 million sale to Concentra Biosceinces
- Disc Medicine in connection with its reverse merger transaction with Gemini Therapeutics
- Entrada Therapeutics in connection with its global collaboration with Vertex Pharmaceuticals
- Convergent Dental in connection with its Series C, Series D and convertible note financings
Areas of Practice
Credentials
Education
LLM2018
New York University School of Law
LLM2017
Renmin University of China
LLB2015
Renmin University of China
Admissions
Bars
- New York